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The use of spinal cord electrical stimulation
(SCS) has been effectively used to control chronic
pain syndromes, such as lumbosacral arachnoiditis
and reflex sympathetic dystrophy, in patients refrac-
tory to traditional analgesic medication therapy for
almost two decades. During the past 10 years, clini-
cal investigators have found that this technique can
be useful for controlling chronic ischemic pain expe-
rienced by patients with endstage lower extremity
circulatory insufficiency and that some patients actu-
ally have trophic skin lesions of the feet heal as well.
Unfortunately, most clinical information regarding
the use of this technique in management of ischemic
limb pain is based on the evaluation of small num-
bers of questionably selected patients with no stan-
dardized controls against which to measure outcome
differences. This European multicenter randomized
study has been able to stratify a reasonably large
number of patients who meet objective criteria for
the term “unreconstructable peripheral occlusive
disease” and to allocate them to either a best med-
ical management treatment group or best medical
management plus SCS treatment group with follow-
up for up to 24 months. This would be quite diffi-
cult to accomplish at any single treatment center.
Sophisticated microvascular testing performed on all
patients included capillary microscopy, transcuta-
neous oxygen pressure, and laser Doppler scan per-
fusion measurements. These tests were used to cate-
gorize the microcirculatory status of individuals in
the study and as a means of measuring response to
SCS. Transcutaneous oxygen pressure measure-
ments and the capillary microscopy were felt to be
the most useful tests. Patients in both treatment
groups were characterized as having poor, interme-
diate, or good microcirculation on the basis of the
objective results of these tests, which are explained
in the text.
Critical end points for outcomes assessment
between the two groups included pain control, limb
salvage, and patient death. Analgesic use was quan-
tified by means of the Medication Quantification
Scale. Limb salvage definition necessitated preserva-
tion of the forefoot. Conclusions of this study sug-
gest that pain control is more effective in the SCS
group than in the more conservatively treated
group. Furthermore, the study concludes that there
was no statistical difference in death rate or major
amputation rate between the two treatment groups.
An interesting caveat suggests a significant reduction
in major amputations (below knee/above knee)
when SCS is used to treat patients with intermediate
microcirculatory insufficiency. The authors conclude
that noninvasive testing may be useful for the selec-
tion of patients whose conditions might respond to
SCS and suggest that the use of SCS should be
restricted to potential responders. Without further
prospective clinical study, the benefit of SCS in the
management of endstage vascular disease cannot be
established.
This paper does not try to explain the mecha-
nism whereby SCS enhances microcirculatory perfu-
sion to the threatened ischemic limb. It does, how-
ever, support the concept that a predictable micro-
circulatory enhancement response to SCS cannot be
anticipated with tests (such as angiography, plethys-
mography, or duplex ultrasound scanning), which
are commonly used to evaluate extremity circula-
tion. The authors focus attention on the need to
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objectively assess the microcirculation of ischemic
limbs with noninvasive testing. Numerous theories
have been proposed to explain why SCS improves
microcirculation in some individuals. Patients who
obtain the best pain relief also appear to experience
the most improvement in microcirculatory perfusion
of the ischemic limb. This in turn correlates with
occasional healing of trophic lesions.
This study does not justify the wide spread use of
SCS for the treatment of endstage ischemic disease.
SCS is not cheap (global cost, $25,000 to $30,000).
The Health Care Financing Administration and
Medicare will allow SCS to be used for the treatment
of intractable pain caused by endstage vascular disease
in selected circumstances. Until efficacy can clearly be
established, this procedure should be considered
investigational and should be subjected to same scien-
tific scrutiny necessary for any new therapy.
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